A retrospective analysis of respiratory virus transmission before and during the COVID-19 pandemic in Pune the western region of India

Sumit Bhardwaj1, Manohar Lal Choudhary1, Sheetal Jadhav1, Veena Vipat1, Rohan Ghuge1, Sonali Salvi2, Rajesh Kulkarni2, Aarti Kinikar2, Vikram Padbidri3, Sanjay Bafna3, Ashish Bavdekare4, Pradeep D’costa4, Nilesh Gujar5 and Varsha Potdar1*

1Influenza, National Institute of Virology (ICMR), Pune, India, 2B. J. Medical College and Sassoon Hospital, Pune, India, 3Microbiology, Jehangir Hospital, Pune, India, 4KEM Hospital Research Centre, Pune, India, 5Gujar Children Hospital, Pune, India

Background: SARS-CoV-2 was first reported in China in December 2019 and quickly spread across the world. Non-pharmaceutical interventions (NPIs) are the key to control the transmission of respiratory viruses. To stop the spread, NPI is widely recommended and is still followed by most countries.

Methods: At the National Influenza Center of the Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), the surveillance of severe acute respiratory illness and acute respiratory illness cases for influenza and other respiratory viruses is in place. In this study, we analyzed surveillance data on respiratory viruses and/or SARS-CoV-2 testing from January 2017 to December 2021. Multiplex real-time PCR was used to detect the respiratory viruses.

Results: Our findings indicate that during the pandemic, the positivity for influenza A and B, metapneumovirus, parainfluenza virus, respiratory syncytial virus, and human coronavirus declined significantly.

Conclusion: The annual distinct seasonal outbreaks of influenza, RSV, and other respiratory viruses as observed during the pre-COVID-19 period were not observed during the COVID-19 pandemic in years 2020 and 21. Social distancing, lock-downs, and non-pharmaceutical interventions may play an important role in the reduction of respiratory viruses. Understanding the seasonal respiratory virus decline could help public health experts prepare for future respiratory virus pandemics.

KEYWORDS
COVID-19, influenza, pandemic, non-pharmaceutical interventions, viral respiratory viruses
Introduction

In adults, a Human metapneumovirus (hMPV) and human coronaviruses (CoV), as well as adenoviruses (AdV) and parainfluenza viruses (PIV) are all respiratory viruses that contribute to both morbidity and mortality (1, 2), particularly among older and vulnerable adult populations (3). Furthermore, they account for huge economic expenses on a global scale each year (4). Non-pharmaceutical interventions (NPIs) to control the transmission of respiratory viruses are essential since pharmacological treatment options for most of these viruses are limited. SARS-CoV-2 was first reported in China in December 2019 and quickly spread across the country. Governments have adopted various non-pharmacological public health measures, such as mask use, social isolation, and hand hygiene, to try to minimize the spread of SARS-CoV-2. Prevention is critical when dealing with a disease that lacks a particular therapy to reduce morbidity and death. Vaccination has the potential to be a very successful future preventative method (5–9). NPI’s are mainly recommended and is still widely recommended by most countries to stop the spread of SARS-CoV-2. According to national recommendations, the general populace used face masks, maintained social distance, performed basic hand hygiene, cleaned surfaces, and ventilated interior spaces (10). During lockdown, religious institutions, schools, and malls were closed, and social and religious gatherings were restricted, resulting in a significant loss of social connections. Even though there is currently widespread agreement regarding their efficacy in containing SARS-CoV-2 (11). Based on data from India’s national influenza center surveillance system, which tracks ARIs, particularly influenza, from 2017 to 2021, especially from the western region of India, we demonstrate that the restrictions prevented not just the spread of SARS-CoV-2, but also the transmission of other viral diseases as a result of the restrictions.

Methods

This retrospective study was carried out by the National Influenza Center of the Indian Council of Medical Research-National Institute of Virology (ICMR-NIV). From January 2017 to December 2021, we gathered epidemiological and laboratory diagnosis data on respiratory virus and/or SARS-CoV-2, and analyzed for two periods as pre-pandemic period January 2017–March 2020 and pandemic period April 2020–December 2021. The analyzed data are part of the ongoing surveillance of Influenza and other respiratory viruses. The study center recruited participants from sentinel hospitals and clinics with general medical and pediatric departments from Pune, India. The institutional human ethics committee’s approval was obtained. The research was explained to the participants in their local language, and written consent or assent was obtained before enrollment. Acute respiratory infection (ARI) was defined in the case definitions used to enroll participants as cases presenting in the outpatient department (OPD) with an acute onset (within 7 days) of at least two of the following symptoms: fever/feverishness, chills, cough, nasal congestion, shortness of breath, or sore throat. Patients with modified SARI were defined as those who had a history of cough that began during the past seven days and that required overnight hospitalization. SARI was defined in babies < 2 months of age as a physician diagnosis consistent with an acute lower respiratory illness.

TABLE 1 Characteristics of patients tested for respiratory viruses other than SARSCoV-2 between January 2017 and May 2021.

|                          | January 2017–March 2020 | April 2020–December 2020 (P1) | Jan 2021–December 2021 (P2) |
|--------------------------|-------------------------|-------------------------------|----------------------------|
|                          | Pre–Pandemic No.        | Early Stage of Pandemic No.   | Later Stage of Pandemic No. |
|                          | Percent                 | Percent                       | Percent                    |
| Sample tested            | 5190                    | 3206                          | 1217                       |
| Male                     | 2928                    | 1977                          | 672                        |
| Mean age (years)         | 19.3                    | 41                            | 22                         |
| Age in years             |                         |                               |                            |
| < 2                      | 1317                    | 252                           | 375                        |
| 2–<5                     | 799                     | 69                            | 170                        |
| 5–<15                    | 1007                    | 154                           | 139                        |
| 15–<45                   | 1190                    | 1205                          | 260                        |
| 45–<60                   | 401                     | 694                           | 111                        |
| >60                      | 476                     | 832                           | 162                        |
| Type of sample           |                         |                               |                            |
| ARI                      | 1730                    | 830                           | 313                        |
| SARI                     | 3460                    | 2376                          | 904                        |
TABLE 2 Comparison of positivity rates of respiratory viruses other than SARSCoV-2 between January 2017–March 2020 (pre–pandemic period) and April 2020–December 2021 (during pandemic period).

|                       | January 2017–March 2020 (P1) | March 2020–December 2020 (P2) | P1 vs P2 | Jan 2021–December 2021 (P3) |
|-----------------------|------------------------------|-------------------------------|----------|----------------------------|
|                       | Pre–Pandemic | Early Stage of Pandemic | Later Stage of Pandemic |                       |
| No.                  | Percent       | No.             | Percent     | No.            | Percent     |
| Overall positivity   | 1708          | 32.9%           | 107              | 3.3%            | <0.001      | 550           | 45.2%         |
| Influenza A(H1N1) pdm09 | 422            | 8.1%            | 5               | 0.2%            | <0.001      | 10            | 0.8%          |
| Infl A (H3N2)        | 75             | 1.4%            | 13              | 0.4%            | <0.001      | 73            | 6.0%          |
| Infl B               | 165            | 3.2%            | 3               | 0.1%            | <0.001      | 93            | 7.6%          |
| RSV                  | 394            | 7.6%            | 18              | 0.6%            | <0.001      | 332           | 27.3%         |
| HMPV                 | 170            | 3.3%            | 2               | 0.1%            | <0.001      | 5             | 0.4%          |
| PIV 1–4              | 165            | 3.2%            | 36              | 1.1%            | <0.001      | 15            | 1.2%          |
| Adenovirus           | 153            | 2.9%            | 18              | 0.6%            | <0.001      | 9             | 0.7%          |
| Rhinovirus           | 164            | 3.2%            | 12              | 0.4%            | <0.001      | 13            | 1.1%          |

Positive for Any of the respiratory virus

| < 2 yrs | 45.6% | 18.7% | <0.001 | 72.8% |
| 2–<5 yrs | 43.2% | 17.4% | <0.001 | 70.0% |
| 5–<15 yrs | 26.5% | 14.3% | <0.001 | 57.6% |
| 15–<45 yrs | 19.6% | 1.3%  | <0.001 | 14.6% |
| 45–<60 yrs | 23.9% | 0.9%  | <0.001 | 7.2%  |
| >60 yrs | 18.3% | 1.9%  | <0.001 | 4.9%  |

SARS CoV-2

| < 2 yrs | NA | NA | 2 | 0.8% | 0 | 0.0% |
| 2–<5 yrs | NA | NA | 5 | 7.2% | 1 | 0.6% |
| 5–<15 yrs | NA | NA | 6 | 3.9% | 4 | 2.9% |
| 15–<45 yrs | NA | NA | 207 | 17.2% | 33 | 12.7% |
| 45–<60 yrs | NA | NA | 150 | 21.6% | 28 | 25.2% |
| >60 yrs | NA | NA | 153 | 18.4% | 38 | 23.5% |

respiratory infection (pneumonia, bronchitis, bronchiolitis, sepsis) necessitating overnight hospitalization. The four sentinel hospitals represented both the public and private sectors. Center recruited 10–20 ARI and SARI patients each week from sentinel hospitals across all age categories. Throughout the research period, participants were recruited via convenient sampling. Additional individuals were added during a surge of respiratory illnesses in the community or hospital. Physicians and nurses at all sentinel locations were trained to screen patients using the ARI and SARI case criteria. Each recruited participant’s clinical and epidemiological data were documented on a standardized case report form. Clinical samples i.e., nasal/throat swab were collected, transported, and stored in accordance with WHO recommendations (12). Trained staff collected nasal, throat, or nasopharyngeal respiratory specimens (according to age) and transported them to the laboratory within 24 h while maintaining a cold chain. RNA was extracted according to the manufacturer’s procedure using a MagMax-96 kit. All specimens were tested for the following viruses using the real-time reverse transcription polymerase chain reaction (rRT-PCR): [influenza A(H1N1) pdm09, A (H3N2)], influenza B [B/Yamagata and B/Victoria] along with the house-keeping RNaseP gene (CDC, WHO), respiratory syncytial virus A and B, metapneumovirus, parainfluenza virus 1,2,3,4, rhinovirus and SARS-CoV-2 (13–15). A one-step reverse transcriptase polymerase chain reaction was used to amplify nucleic acids (qRT-PCR SuperScript TM III kit, Invitrogen, USA). A 25 ul PCR reaction included 10 PM of forward and reverse primers, five PM of TaqMan probe, 12.5 milliliters of 2X buffer, 0.5 milliliters of SuperScriptTM III enzyme, and five milliliters of nucleic acid templates. Thermal cycling conditions were as follows: 30 min at 50°C for reverse transcription, 5 min at 94°C for initial denaturation, 45 cycles of three stages—15 sec at 94°C, 15 sec at 50°C, and 30 sec at a 55°C incubation step for data collection. Allelic discrimination was used to identify an oseltamivir-resistant A/H1N1pdm virus with the H275Y mutation [Neuraminidase (NA)] in clinical specimens or clinical isolates, using the RT-PCR procedure given by the National Institute of Health, Thailand.

Data were entered into Epi-info 7 (TM), which was compiled weekly. The epidemiological week and seasonality were calculated based on the day of illness onset. Weekly data
was then shown as percent positive for each virus over the course of an epi-year (since the beginning of analysis). We used the chi-square test to determine the statistical significance of the proportions. The study duration was divided into pre-pandemic (January 2017 to March 2020) and pandemic (April 2020 to December 2021); post-pandemic was further divided into P1: early stages of pandemic (April 2020 to December 2020) and P2: late stages of pandemic (January 2021 to December 2021).

Results

During the research period, 9,613 patients were tested for respiratory viruses and analyzed. 5190 were studied between January 2017 and March 2020; 3206 between April and December 2020; and 1,217 between January and December 2021. Table 1 summarizes the patient demographic characteristics. From March 2020, as the number of COVID-19 infections grew, the number of tests needed by doctors increased proportionately (32/week during the pre-pandemic period vs. 47/week during the pandemic). More importantly, during the early stages of the pandemic (P1), the overall test positivity for non-SARS CoV-2 respiratory viruses was lower than it had been in the previous years (3.3 vs. 33.9%, respectively, p 0.0001). The test positivity increased to 45% in the latter part of 2021. Demographic characteristics indicate that male gender was more common (56.4 vs. 61.7%, p 0.0001) and the median age was higher (19.3 years vs. 41 years, p 0.0001) in the adult population examined during the pandemic era (P1). The rate of positives for each respiratory virus examined throughout the research period is shown in Table 2. The test positivity for influenza A(H1N1) pdm09, influenza A (H3N2), influenza B, HMPV, PIV1-4, RSV A & B, AdV, and rhinovirus significantly decreased during the pandemic, especially in the early stages of the pandemic when government restrictions were more stringent. Children under the age of five were found to have the highest levels of viral positivity both before and during the pandemic. However, when compared to the period before the pandemic, their positivity decreased significantly during the early stages of the pandemic (P1) (18.4% vs. 44.7 %, p 0.0001). When other respiratory virus-positive subjects were stratified by age, the same results were obtained. Similar findings were found when additional respiratory virus-positive participants were stratified by age (Supplementary Table 1). The viral positivity for ARI cases was higher among all viruses compared to SARI cases except for rhino and adenovirus (Supplementary Table 3) Before the pandemic, influenza virus activity was usually at its highest between June and September, with an intersessional surge in February and March (Figure 1). However, during the pandemic period, no influenza activity was observed during the early stages (P1). From August to December 2021, both influenza A and B activity were seen without regard to seasonal patterns. Prior to the pandemic, RSV, HMPV, PIV1-4, and AdV circulated from monsoon to winter, peaking between September...
TABLE 3 Co-infection during the study period.

| January 2017–March 2020 | H1N1 | H3N2 | B Victoria | B Yamagata | RSV | PIV | HMPV | Adenovirus | Rhinovirus |
|--------------------------|------|------|------------|------------|-----|-----|------|------------|------------|
| H1N1 pdm09               | 0    | 0    | 0          | 11         | 2   | 2   | 1    | 2          |            |
| H3N2                     | 0    | 0    | 0          | 1          | 0   | 1   | 0    |            |            |
| B Victoria               | 0    | 1    | 1          | 0          | 1   |     |      |            |            |
| B Yamagata               | 1    | 0    | 0          | 0          | 0   |     |      |            |            |
| RSV                      | 7    | 3    | 8          | 15         |     |     |      |            |            |
| PIV                      |      | 1    | 4          | 4          |     |     |      |            |            |
| HMPV                     |      |      | 4          | 3          |     |     |      |            |            |
| Adenovirus               |      |      |            |            | 5   |     |      |            |            |
| Rhinovirus               |      |      |            |            |     |     |      |            |            |

| April 2020–December 2021 | H1N1 | H3N2 | B Victoria | B Yamagata | RSV | PIV | HMPV | Adenovirus | Rhinovirus | SARS CoV–2 |
|--------------------------|------|------|------------|------------|-----|-----|------|------------|------------|------------|
| H1N1 pdm09               | 1    | 0    | 0          | 1          | 1   | 0   | 0    | 0          | 0          |            |
| H3N2                     | 1    | 0    | 7          | 0          | 0   | 1   | 1    |            |            |            |
| B Victoria               | 0    | 8    | 0          | 2          | 0   |     |      |            |            |            |
| B Yamagata               | 0    | 0    | 0          | 0          | 0   |     |      |            |            |            |
| RSV                      | 4    | 0    | 4          | 1          | 0   |     |      |            |            |            |
| PIV                      | 0    | 1    | 1          | 0          |     |     |      |            |            |            |
| HMPV                     | 0    |      | 0          | 0          |     |     |      |            |            |            |
| Adenovirus               |      |      |            |            | 0   |     |      |            |            |            |
| Rhinovirus               |      |      |            |            |     |     |      |            |            |            |
| SARS CoV–2               |      |      |            |            |     |     |      |            | 1           |            |

and December, while during the pandemic, they were detected only in the latter half of the 2021 (P2), with essentially little activity of positive cases in the early stages of the pandemic (P1). Additionally, certain coinfections were also identified (Table 3) (79/5190 [1.5%] before the pandemic, 35/4427 [0.7%] during the pandemic). However, no correlation of co-infection with clinical outcome was observed. On January 30, 2020, India reported its first COVID-19 case. Immediately following the case’s emergence, the government enacted various community-based mitigating strategies, including school closures and social isolation (Supplementary Table 2). Following the index case in India, SARS-CoV-2 has become the primary cause of respiratory infections.

Discussion

Our study suggests that the NPI’s used to contain the spread of COVID-19, such as social isolation, face mask use, and increased hand hygiene, may also help prevent the spread of other respiratory virus infections that are transmitted in a similar manner to SARS-CoV-2. During the early stage (P1) of the COVID-19 pandemic, a significant decline in the prevalence of RSV, influenza A and B, hMPV, and PIV was seen in comparison to previous years. We also noticed a significant decrease in the frequency of hAdV and rhinoviruses, but not as substantially as other respiratory viruses. Notably, our data indicated that the most prevalent seasonal viruses (e.g., hRSV, influenza, PIV, and hMPV) were severely limited during the COVID-19 pandemic, particularly during the early stages. Recent investigations globally have shown similar findings (16–19). This fall in non-SARS-CoV-2 respiratory virus detection is consistent with studies from the United States and the United Kingdom suggesting an early termination to the 2019/2020 influenza season and a decline in other virus detection during the pandemic’s early phases (18, 20). Additionally, multiple studies conducted in different countries discovered a considerable decline in influenza virus detection during the early stages of the COVID-19 pandemic (21–25). Other research (20, 22, 26–30) shows that the pandemic interrupted respiratory viral circulation, even though the amount of this impact differed amongst the viruses investigated. We observed that influenza and other respiratory viruses dramatically decreased in frequency during the COVID-19 pandemic. We previously established that these viruses exhibit seasonality and consecutive seasonal epidemic patterns, but respiratory virus epidemic patterns have changed substantially in the aftermath of the introduction of SARS-CoV-2. Following that, in March 2020, the
influenza virus was transmitted at very low levels, with just a few cases recorded over the 2020 season. According to these results, research conducted in the United States of America discovered that positive rates decreased dramatically during the lockdown and remained low during the inter-seasonal circulation (20). We discovered that a decrease in constraints on population movement in the second half of 2021 resulted in an increase in the spread of influenza viruses, hPIV, hRSV, hMPV, and hAdv. Our study group found that males had a higher rate of respiratory virus positivity than females, which is consistent with the literature (31.9 vs 30.5% in the pre-pandemic and 30.2 vs. 26% during the pandemic). A similar observation was made by Jeon et al. in Northern United Arab Emirates (52.8 vs. 50%) (31). According to Rath et al., among hospitalized patients with influenza, men had a greater incidence of positive tests than females, and this was especially true in males (56 vs. 44%) (32). As shown in US data by Kim et al., the adjusted risk ratio for intensive care unit admission in men is 1.34 times higher than in females (33). These findings suggest that males are more likely than females to be hospitalized for respiratory viruses, which may explain the high male rate in our patient population. Our investigation found few respiratory co-pathogens in COVID-19 individuals. This discovery might have a considerable influence on the diagnostic flow of ARI patients in high-COVID-19 prevalence areas, casting doubt on the necessity to look for viruses other than SARS-CoV-2 right away. Our results support a growing body of literature demonstrating that strict public health interventions, including regional lockdowns, border closures, handwashing, and facemask usage, may greatly reduce the transmission of epidemic respiratory viruses. Despite the continuous identification of SARS-CoV-2, this research is notable for the reported substantial drop in non-SARS-CoV-2 respiratory viruses. This might be because of increased SARSCoV-2’s transmissibility compared to other respiratory viruses, which outcompete seasonal respiratory viruses, which are more readily influenced by SARSCoV-2 transmission mitigation efforts. It is now difficult to say if viral-viral interactions between SARSCoV-2 and other respiratory viruses are also contributing to the observed drop in circulation. Nickbakhsh et al. hypothesized that viral interference may be achieved by interferon-mediated mechanisms (34). The study’s strength comes from the utilization of data from a robust surveillance system that was in operation during the COVID-19 pandemic in 2020, as well as a well-defined case definition. In addition, the data includes hospital surveillance from both the OPD and the IPD. Consequently, this research looked at even the less critical cases that did not need hospitalization. This study may have a number of potential limitations. This is retrospective observational research, so it is impossible to say if the observed decline is due to multilayered public health efforts focused on preventing the spread of SARSCoV-2 or other unknown causes. In addition, the sample is convenient, which may not reflect the total number of patients that visit the OPD and IPD. To delimit these limitations in future, more structured way of data collection and enumerating the number of cases seeking care for ARI would be important to understand the multipliers for estimate generation.

In conclusion, the annual seasonal outbreak for most non-SARS-CoV-2 respiratory viruses is missing in 2020/21. An unknown number of variables including non-pharmaceutical interventions might be responsible for this drastic drop. Stringent SARSCoV-2 containment likely reduced the spread of other respiratory viruses. However, the function of SARSCoV-2 in viral displacement and interference is unknown. For public health purpose, understanding how seasonal respiratory viruses decline may prevent future seasonal respiratory virus epidemics and prepare for future respiratory virus pandemics.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by ICMR-NIV, Pune. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

Author contributions

SB: conceptualization, data curation, formal analysis, writing—original draft, writing—review, and editing. MC: conceptualization, validation, data curation, and administration. SJ: investigation and data curation. VV: investigation. RG: formal analysis. SS, RK, AK, ViP, SB, AB, PD’c, and NG: investigation. VaP: conceptualization, funding acquisition, methodology, project administration, resources, supervision, writing—review, and editing. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those
References

1. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. (2018) 392:1789–858. doi: 10.1016/S0140-6736(18)32379-7

2. Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. (2018) 392:1736–88. doi: 10.1016/S0140-6736(18)32203-7

3. Blackburn R, Zhao H, Pebody R, Hayward A, Warren-Gash C. Laboratory-confirmed respiratory infections as predictors of hospital admission for myocardial infarction and stroke: Time series analysis of English data for 2004–2015. Clin Infect Dis. (2018) 67:8–17. doi: 10.1093/cidi/ctx1144

4. Fendrick A, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza virus respiratory tract infection in the United States. Arch Intern Med. (2003) 163:487–94. doi: 10.1001/archinte.163.4.487

5. Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. (2021) 21:73–82. doi: 10.1038/s41577-020-00480-0

6. Polack FP, Szankowski S, Kitchin N, Absalon J, Gurumurthy A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. (2020) 385:2603–15. doi: 10.1056/NEJMoa2034577

7. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. (2021) 397:1879–93. doi: 10.1016/S0140-6736(20)34661-6

8. Wang Z, Schmidt E, Weissblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-elicted antibodies to SARS-CoV-2 and circulating variants. Nature. (2021) 592:616–22. doi: 10.1038/s41586-021-03324-6

9. Fiocchi A, Jensen-Jarolim E. SARS-CoV-2 vaccine, can you be over it. World Allergy Organ J. (2021) 14:100154. doi: 10.1016/j.waojou.2021.100154

10. CIRCULARS FOR COVID-19. Available online at: https://www.mha.gov.in/sites/default/files/PR_ConsolidatedGuidelinesofMHA_28032020_0.pdf (accessed August 26, 2022).

11. Jefferson T, Del Mar CB, Dooley L, Ferroni E, Al-Ansary LA, Barer M, et al. Respiratory virus detection among the overseas returnees during the early COVID-19 Outbreak in Japan. JAMA. (2021) 325:1396–7. doi: 10.1001/jama.2021.6173

12. Lee H, Lee H, Song KH, et al. Impact of public health interventions on seasonal influenza activity during the COVID-19 Outbreak in Korea. Clin Infect Dis. (2020) 11:CD000620. doi: 10.1021/acs.jmedchem.7b01039

13. CDC protocol of realtime RTPCR for swine influenza A(H1N1) 2009. Available online at: https://www.cdc.gov/h1n1flu/lab/ (accessed August 26, 2022).

14. Koul PA, Mir H, Saha S, Chadha MS, Potdar V, Widdowson MA, et al. Respiratory viruses in returning Hajj & Umrah pilgrims with acute respiratory illness in 2014-2015. Indian J Med Res. (2018) 148:329–33. doi: 10.4103/ijmr.IJMR_890_17

15. Potdar V, Choudhary ML, Bhardwaj S, Ghuge R, Sugunan AP, Gurur V, et al. Respiratory virus detection among the overseas returnees during the early phase of COVID-19 pandemic in India. Indian J Med Res. (2020) 151:486–9. doi: 10.4103/ijmr.IJMR_658_20

16. Redlberger-Fritz M, Kundt M, Aberle SW, Puchhammer-Stöckl E. Significant impact of nationwide SARS-CoV-2 lockdown measures on the circulation of other respiratory virus infections in Austria. J Clin Virol. (2021) 137:104795. doi: 10.1016/j.jcv.2021.104795

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2022.936634/full#supplementary-material
32. Rath B, Conrad T, Myles P, Alchikh M, Ma X, Hoppe C, et al. Influenza and other respiratory viruses: standardizing disease severity in surveillance and clinical trials. Expert Rev Anti Infect Ther. (2017) 15:545–68. doi: 10.1080/14787210.2017.1295847

33. Kim L, Garg S, O’Halloran A, Whitaker M, Pham H, Anderson EL, et al. Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET). Clin Infect Dis. (2021) 72:e206–14. doi: 10.1093/cid/ciaa1012

34. Nickbakhsh S, Mair C, Matthews L, et al. Virus-virus interactions impact the population dynamics of influenza and the common cold. Proc Natl Acad Sci U S A. (2019) 116:27142–50. doi: 10.1073/pnas.1911083116